Endothelin (ET) is a recently discovered 21 ... The effects of ET are mediated through interaction with two classes of cell surface receptors. The type A receptor (ET-A) has been associated ...

Article Google Scholar Ogawa Y, Nakao K, Arai H, Nakawaga O, Hosoda K, Suga SI, Nakanishi S, Imura H: Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biophys Biochem ...

Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist ...

ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A) receptor antagonist avosentan in patients with diabetic nephropathy. The study ...

Researchers at University of Tsukuba used cryo-electron microscopy to examine the complex structure of the endothelin receptor and G protein, which are crucial for signal transduction at the cell ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinuria in patients with IgA nephropathy are incompletely understood. We are conducting a ...

One type of drug used to treat PAH is endothelin receptor antagonists. ERAs, as they are called, help keep blood vessels from narrowing. But these drugs don’t work as well for Black patients as ...

In testing responses to endothelin receptor antagonists, a type of therapy for PAH, women and white people were shown to respond more significantly to the treatment than men or Black people.

Atrasentan previously demonstrated efficacy in the open-label AFFINITY basket trial, where it reduced the 24-hour urinary ...

Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of ...